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The human ether-a-go-go-related gene 1 (hERG1) encodes the
pore-forming subunit of the rapidly activating delayed rectifier
potassium channel. Several hERG1 isoforms with different
N- and C-terminal ends have been identified. The hERG1a,
hERG1b, and hERG1-3.1 isoforms contain the full-length C terminus, whereas the hERG1USO isoforms, hERG1aUSO and
hERG1bUSO, lack most of the C-terminal domain and contain a
unique C-terminal end. The mechanisms underlying the generation of hERG1USO isoforms are not understood. We show that
hERG1 isoforms with different C-terminal ends are generated
by alternative splicing and polyadenylation of hERG1
pre-mRNA. We identified an intrinsically weak, noncanonical
poly(A) signal, AGUAAA, within intron 9 of hERG1 that modulates the expression of hERG1a and hERG1aUSO. Replacing
AGUAAA with the strong, canonical poly(A) signal AAUAAA
resulted in the predominant production of hERG1aUSO and a
marked decrease in hERG1 current. In contrast, eliminating the
intron 9 poly(A) signal or increasing the strength of 5ⴕ splice site
led to the predominant production of hERG1a and a significant
increase in hERG1 current. We found significant variation in the
relative abundance of hERG1 C-terminal isoforms in different
human tissues. Taken together, these findings suggest that posttranscriptional regulation of hERG1 pre-mRNA may represent a
novel mechanism to modulate the expression and function of
hERG1 channels.

The human ether-a-go-go-related gene 1 (hERG1)3 encodes a
K channel that has properties similar to the rapidly activating
delayed rectifier K⫹ current (IKr) in the heart (1– 4). hERG1
channels play an important role in cardiac action potential
repolarization, and mutations in hERG1 cause long QT syndrome type 2 (5). Several hERG1 isoforms with different N- and
C-terminal ends have been identified (4, 6). The first cloned
hERG1 isoform, hERG1a, consists of 1159 amino acids (1). The
hERG1b isoform lacks the first 376 amino acids of hERG1a and
has an alternate 36-amino acid N-terminal end (7, 8). The
⫹
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hERG1-3.1 isoform lacks the first 102 amino acids of hERG1a,
which are replaced by 6 unique amino acids (9). The C-terminal
isoforms, hERG1aUSO and hERG1bUSO, contain the hERG1a
and hERG1b N-terminal ends, respectively, but lack the last 359
amino acids, which are replaced by an alternate 88-residue
C-terminal end (6, 10, 11). For simplicity, we refer to hERG1
isoforms with the full-length C terminus as hERG1FL, and
hERG1 isoforms with the USO C terminus as hERG1USO. The
mechanisms responsible for the generation of hERG1 N-terminal isoforms have been well characterized (12, 13), however, the
molecular determinants that generate hERG1 C-terminal isoforms are not fully understood.
Functional studies have shown that hERG1a, hERG1b, and
hERG1-3.1 channels generate K⫹ currents with distinct gating
properties (2, 3, 7–9). Recently, it was suggested that native
ventricular IKr channels are heterotetramers containing
hERG1a and hERG1b subunits (14). hERG1aUSO has been
reported to generate the hERG1 current with markedly reduced amplitude when expressed in Xenopus oocytes (15).
However, when expressed in mammalian Ltk⫺ or HEK293
cells, hERG1aUSO and hERG1bUSO fail to form functional channels (10, 11). Coexpression of hERG1a with hERG1aUSO in
equimolar concentrations has no obvious effect on the
hERG1a-mediated current (10). When an excess of hERG1aUSO
or hERG1bUSO is coexpressed with hERG1a or hERG1b, a
decrease in hERG1 current is observed (10, 11). Biochemical
studies have shown that hERG1USO-containing heterotetrameric channels are retained in the endoplasmic reticulum
and degraded by the ubiquitin-proteasome pathway (11). Specific knockdown of hERG1USO isoforms by RNA interference
increases the functional expression of hERG1a/b channels.
These previous studies suggest that the function and trafficking
of hERG1USO isoforms are significantly impaired in comparison to hERG1FL isoforms and that hERG1USO isoforms may
post-translationally suppress hERG1a/b channel function (11).
Therefore, regulation of hERG1 C-terminal isoform expression
has significant functional consequences.
In the present study, we show that the generation of hERG1a
and hERG1aUSO isoforms results from the alternative splicing
and polyadenylation of hERG1 pre-mRNA. The strengths of the
5⬘ splice site and poly(A) signal of intron 9 play an important
role in determining the relative expression of hERG1a and
hERG1aUSO and thus, regulating hERG1 channel function. The
alternative processing of hERG1 pre-mRNA may represent a
novel post-transcriptional mechanism to modulate the expression and function of hERG1 channels.
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EXPERIMENTAL PROCEDURES
Rapid Amplification of cDNA End-Poly(A) Test (RACE-PAT)—
RACE-PAT assay was performed as described (16). Human
heart mRNA was purchased from Clontech. First-strand cDNA
was synthesized by reverse transcription with an oligo(dT)
primer linked to a C/G-rich anchor sequence (5⬘-CGAGCTCCGCGGCCGCG(T)12-3⬘). Subsequent PCR amplification was
performed using a reverse primer with only the anchor
sequence without oligo(dT) (R2, 5⬘-GCGAGCTCCGCGGCCGCG-3⬘) and the hERG1USO specific forward primer (F1,
5⬘-GCAGATATAGCAAGCTCTTTCGACCATAG-3⬘). The
control PCR was carried out using the F1 primer and a reverse
primer upstream and adjacent to the intron 9 poly(A) signal
(R1, 5⬘-GAAAGAACATACAGTAGTATAGCTTAG-3⬘). The
PCR products were visualized on a polyacrylamide gel stained
with ethidium bromide.
Plasmid Constructs and Transfection—The poly(A) reporter
construct was generated by introducing tandem poly(A) sites
into a modified pGL3 vector (Promega, Madison, WI), in which
the synthetic poly(A) signal upstream of the SV40 promoter
was removed. The construct contained the SV40 promoter, the
firefly luciferase gene, and 308 bp of the hERG1 intron 9 followed by a synthetic poly(A) signal. The 308-bp fragment containing intron 9 poly(A) signal was amplified by PCR and subcloned into pGL3 with XbaI and BamHI, replacing the SV40
poly(A) site of pGL3. A synthetic poly(A) signal fragment was
amplified by PCR using the unmodified pGL3 vector as the
template and inserted at BamHI and SalI sites of the poly(A)
reporter construct. The poly(A) signal mutations were generated by site-directed mutagenesis using the pAlter in vitro
mutagenesis system. HEK293 cells were transiently transfected
with these constructs as described (17).
The hERG1 minigene composed of hERG1 cDNA (exons
1– 6) and hERG1 genomic DNA (intron 6 to poly(A) site) was
constructed by replacing the hERG1a cDNA C-terminal
intronless fragment with the intron-containing hERG1
genomic DNA fragment obtained from a human PAC clone
consisting of hERG1 genomic sequence from intron 6 to the
end of hERG1 gene (PR4-548K24). The minigene was subcloned into a modified pcDNA5 vector, in which the BGH
poly(A) signal was deleted. Mutations of the hERG1 intron 9
poly(A) signal and 5⬘ splice site were generated by site-directed
mutagenesis using the pAlter in vitro mutagenesis system. The
hERG1aUSO cDNA construct was generated by PCR from the
human heart Marathon-Ready cDNA (Clontech) using a forward primer (5⬘-CTGGCCATGAAGTTCAAGACCACAC3⬘) and a reverse primer (5⬘-AGGACTCCCTTTGCTTTGGATGTG-3⬘). The PCR fragment was inserted into pCRII
vector by TA cloning (Invitrogen). The cDNA fragment of
hERG1aUSO was sequenced and subcloned into the backbone
of hERG1a at SphI and EcoRI sites to obtain the full-length
hERG1aUSO cDNA. The hERG1a and hERG1aUSO cDNAs were
subcloned into pcDNA5 vector. Flp-In HEK293 cells (Invitrogen) were stably transfected with pcDNA5 cDNA or minigene
constructs and selected with 100 g/ml of hygromycin B. Flp-In
HEK293 cells, which contain a single integrated Flp recombination target site, allow stable integration of a single copy of the
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cDNA or minigene construct at a specific genomic site and,
subsequently, similar expression in all cell clones.
Quantitative Analysis of hERG1 Transcripts in Human Tissues by Real Time PCR—The human tissue total RNAs were
purchased from Ambion (Austin, TX) and Biochain (Hayward,
CA). cDNAs were synthesized with the SuperScript III First
Strand Synthesis System for RT-PCR with random hexamers
(Invitrogen). PCR was performed on the MX300P real time
PCR machine (Stratagene, La Jolla, CA) using Power SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA).
After denaturing at 95 °C for 10 min, the reaction was run for 40
cycles with denaturation at 95 °C for 15 s, annealing and primer
extension at 60 °C for 1 min. The sequences of the primers used
to distinguish hERG1 C-terminal isoforms were: hERG1FL
forward (5⬘-CTTTGGGGAGCCTCTGAACC-3⬘), hERG1FL
reverse (5⬘-GGACCAGAAGTGGTCGGAGAA-3⬘), hERG1USO
forward
(5⬘-CAGTCACTGGGGCTGTGGA-3⬘),
and
hERG1USO reverse (5⬘-GAGAATGTGGGAACCCCAGAG3⬘). The primers for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were: forward
(5⬘-ACACCATGGGGAAGGTGAAG-3⬘) and reverse (5⬘TGGGTGGAATCATATTGGAACA-3⬘). To take into account the amplification efficiency of each primer set, we used a
plasmid DNA that contains partial cDNAs of hERG1FL,
hERG1USO, and GAPDH as template for generating standard
curves for each primer set. By using a plasmid in which the
hERG1FL and hERG1USO cDNA fragments are at a 1:1 ratio,
equal quantities can be assigned to each dilution point of the
standard curves (18). The amounts of the hERG1FL and
hERG1USO transcripts in the samples were calculated using
MxPro Quantitative-PCR software (Stratagene), and normalized to the amount of the GAPDH transcript in the same
samples.
RNase Protection Assay—RNA isolation and the RNase protection assay (RPA) were performed as previously described
(19). Briefly, antisense RNA riboprobes were transcribed in
vitro in the presence of biotin-14-CTP. Yeast RNA was used as
a control for the complete digestion of the probes by RNase.
The relative intensity of each band was quantified using Scion
Image software (Scion Corp., Frederick, MD) and adjusted for
the number of biotin-labeled cytidines in each protected fragment. For hERG1 minigene experiments, the expression level of
the hygromycin B resistance gene from the pcDNA5 vector was
used as a loading control.
Immunoblot Analysis—Immunoblot analysis was performed
as previously described (17, 20). The cell lysates were subjected
to SDS-polyacrylamide gel electrophoresis and then electrophoretically transferred onto nitrocellulose membranes. The
membranes were incubated with an anti-hERG1 antibody
against the N terminus of hERG1a and hERG1aUSO proteins
(Santa Cruz, Santa Cruz, CA) and visualized with the ECL
detection kit (Amersham Biosciences). The expression level of
hygromycin B phosphotransferase encoded by the hygromycin
B resistant gene in the pcDNA5 vector was used as a loading
control (21). The polyclonal anti-hygromycin B phosphotransferase antibody was custom generated by Genscript (Piscataway, NJ) using a peptide antigen corresponding to the last 14
amino acids (CSGNRRPSTRPRAKE) of hygromycin B phosVOLUME 285 • NUMBER 42 • OCTOBER 15, 2010
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3⬘-poly(A) tail. Interestingly, hERG1 genomic DNA contains a
25-bp poly(A) stretch within intron 9. An alignment of the EST
sequence BQ478289 with human genomic DNA revealed that
the poly(A) tail of the EST matched the intronic sequence of
hERG1 (Fig. 1). It is noted that none of the USO-containing
ESTs have more than 25 adenosines in the poly(A) tails, suggesting that they may result from internal priming (i.e. oligo(dT) primers hybridizing to internal poly(A) stretches
instead of the expected 3⬘ end poly(A) sequence). Because of
RESULTS
this uncertainty, the poly(A) data base did not include
Polyadenylation of hERG1aUSO mRNA—When hERG1aUSO hERG1USO transcripts as polyadenylated hERG1 variants (22).
was originally identified, it was unclear whether hERG1aUSO Therefore, it is important to confirm that hERG1USO tranmRNA was polyadenylated (10). A BLAST search of the human scripts are generated by polyadenylation at the 3⬘ end rather
EST data base revealed that many USO-containing ESTs have a than internal priming.
short poly(A) tail. However, these EST cDNA sequences lack
To examine the polyadenylation status of hERG1USO tranthe canonical poly(A) signal (AAUAAA) upstream of the scripts we performed the RACE-PAT assay outlined in Fig. 2A.
Annealing of the oligo(dT) portion
of the primer to the poly(A) tail can
occur anywhere along the entire
length of the poly(A) tail. Therefore,
a heterogeneous pool of first strand
cDNA, primed at all possible positions along the poly(A) tail, is
synthesized after reverse transcription. Subsequent PCR amplification
FIGURE 1. Sequence comparison of an EST clone (BQ478289) with hERG1 intron 9 of human genomic
DNA. The poly(A) tail in the EST matched the 25-nt poly(A) stretch in hERG1 intron 9. The noncanonical poly(A) using a reverse primer containing
the anchor sequence without olisignal (AGTAAA) is underlined.

photransferase. The anti-hygromycin B phosphotransferase
antibody was affinity purified and used at a 1:2000 dilution.
Patch Clamp Recordings—Membrane currents were recorded in whole cell configuration using suction pipettes as
previously described (17, 20). All patch clamp experiments
were performed at 22–23 °C. The patch clamp data are presented as mean ⫾ S.E. and analyzed by Student’s t test. p ⬍ 0.05
is considered statistically significant.

FIGURE 2. Polyadenylation analysis of hERG1USO transcripts by RACE-PAT. A, schematic outlining the strategy for analyzing poly(A) tail status by RACE-PAT.
Reverse transcription using an oligo(dT) anchor primer can occur anywhere along the stretch of poly(A) tail, generating cDNA products of variable length.
Primers: F1, hERG1USO specific forward primer; R1, reverse primer before the intron 9 poly(A) signal; R2, reverse primer of the anchor sequence without
oligo(dT). B, polyacrylamide gel electrophoresis of PCR products. Lane 1, PCR with F1 and R1 primers. Lane 2, PCR with F1 and R2. C, sequence analysis of a
representative clone that contains an 88-adenosine poly(A) tail.
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performed a well described competition assay using a set of constructs
with tandem poly(A) signals (25,
26). The hERG1 intron 9 poly(A)
signal AGUAAA and flanking
sequences (⫺130/⫹172 bp) were
positioned upstream of a relatively
strong synthetic poly(A) signal (Fig.
3A and supplemental Fig. S1). The
tandem poly(A) signals are in competition with each other and the utilization of the intron 9 poly(A) signal relative to the synthetic poly(A)
signal reflects the relative strength
of the intron 9 poly(A) signal. This
tandem poly(A) construct allows
the experiments to be independent
of transfection efficiency, as the two
products are derived from the same
plasmid (27).
The RNA derived from the tandem poly(A) construct was studied
by RPA using a probe specific to 249
nt of hERG1 intron 9. Two possible
fragments, 158 and 249 nt, can be
generated after RNase digestion
FIGURE 3. Analysis of hERG1 intron 9 poly(A) signal. A, diagram of the tandem poly(A) signal construct
including the SV40 promoter, firefly luciferase gene, hERG1 intron 9 poly(A) signal, and the synthetic poly(A) depending on which poly(A) signal
signal. The RPA probe and RNase-protected fragments corresponding to RNA terminated at the intron 9 is utilized (Fig. 3A). The total length
poly(A) and the synthetic poly(A) sites are indicated. B, RPA analysis of wild-type (WT), mutant (Mut), and of the probe was 379 nt and concanonical (Can) hERG1 intron 9 poly(A) signals. Unt, untransfected control. Quantifications of the ratio of the
tained sequences from the pCRII
intron 9 and synthetic poly(A) signals are shown as the mean ⫾ S.E. from three independent experiments.
vector at both ends. RPA analysis of
go(dT) and a forward primer specific to hERG1USO isoforms the tandem poly(A) construct showed that both the hERG1
yielded a smeared band between 250 and 350 bp (Fig. 2B, lane intron 9 poly(A) signal and the synthetic poly(A) signal were
2). To demonstrate that the smeared band represents used (Fig. 3B, left panel). The ratio of intron 9 to the synthetic
hERG1USO transcripts with different lengths of the poly(A) tail, (intron 9/synthetic) poly(A) signal usage was 2.8 ⫾ 0.1 (n ⫽ 3).
the PCR products from lane 2 were cloned into the pCRII vec- To further define a functional role of this noncanonical poly(A)
tor and 6 clones were sequenced. All 6 clones matched the signal we mutated AGUAAA to CGCAAA and performed RPA
hERG1USO sequences and contained poly(A) tails with 36, 38, analysis using a probe containing the same mutation. The
75, 85, 88, and 97 adenosines (Fig. 2C). This suggests that results showed that transcription was terminated predomihERG1USO transcripts are polyadenylated due to cleavage and nantly at the synthetic poly(A) signal (Fig. 3B, middle panel).
the addition of a poly(A) tail. Although it is not known from this These results suggest that the poly(A) signal AGUAAA in
experiment where the cleavage site is located, the cleavage hERG1 intron 9 contributes to the formation of poly(A) tail of
should occur somewhere along the 25-nt poly(A) stretch. Thus, hERG1USO transcripts.
up to 25 adenosines of the poly(A) tail of hERG1USO transcripts
Previous studies have shown that the noncanonical poly(A)
are from the genomic DNA.
signal AGUAAA is less efficient than canonical poly(A) signal
Identification of an Intrinsically Weak, Noncanonical Poly- AAUAAA (23). To test whether the hERG1 intron 9 noncaadenylation Signal in hERG1 Intron 9—Although the RACE- nonical poly(A) signal is weak, we mutated AGUAAA to the
PAT assay demonstrated that hERG1USO isoforms arise from canonical poly(A) sequence AAUAAA. We performed RPA
alternative polyadenylation, the poly(A) tail of hERG1USO tran- analysis using a probe containing the AAUAAA mutation and
scripts lacks the upstream canonical poly(A) signal AAUAAA. found that the 158-nt protected fragment was predominantly
Examination of the hERG1 genomic intron 9 sequence reveals generated from the intron 9 poly(A) signal (Fig. 3B, right panel).
the presence of a noncanonical poly(A) signal (AGUAAA) at These results strongly suggest that the poly(A) signal in hERG1
the beginning of the 25-nt poly(A) stretch and several putative intron 9 is intrinsically weak due to the presence of the noncaU/GU-rich elements downstream of the poly(A) stretch nonical hexamer AGUAAA.
(supplemental Fig. S1). The AGUAAA sequence has been preDesign of a Minigene System to Study the Alternative Processviously shown to initiate polyadenylation in other genes (23, ing of hERG1—The presence of a poly(A) signal in hERG1
24). To determine whether this intronic poly(A) signal and intron 9 suggests that this intron is alternatively processed durdownstream U/GU elements can elicit polyadenylation, we ing hERG1 pre-mRNA maturation. To study the alternative
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hERG1aUSO isoforms. As shown in
supplemental Fig. S3A, the hERG1
minigene expressed three protein
bands at about 155, 135, and 100
kDa, consistent with the sizes of
hERG1a and hERG1aUSO proteins
expressed from cDNA constructs
(supplemental Fig. S3A, lanes 1, 4,
and 5). The 155-kDa band represents the complex-glycosylated
mature form of the hERG1a protein,
the 135-kDa band represents the
core-glycosylated immature form
of the hERG1a protein (20), and
the 100-kDa band represents the
core-glycosylated form of the
hERG1aUSO protein (11). The protein expression ratio of hERG1aUSO
to hERG1a in the minigene was
1.2 ⫾ 0.2 (n ⫽ 4), which is lower
than the expression ratio of
hERG1aUSO/hERG1a transcripts.
This is likely due to degradation of
the hERG1aUSO protein by the proFIGURE 4. Effect of poly(A) signal mutations on the alternative processing of hERG1 mRNA. A, diagram of teasome pathway (11).
the hERG1 minigene structure. Splicing intron 9 generates the full-length hERG1a isoform. Polyadenylation at
The Relative Strength of the Intron
the noncanonical poly(A) site in intron 9 generates the truncated hERG1aUSO isoform. B, RPA analysis of the
9
Poly(A)
Signal Alters the Ratio of
minigenes carrying the wild-type (WT), canonical (Can), and mutant (Mut) intron 9 poly(A) signals. Unt, untransfected control. The expression level of the hygromycin B resistance gene served as the loading control. Quan- hERG1a to hERG1aUSO Transcripts
tifications of the hERG1aUSO to hERG1a ratio are shown as the mean ⫾ S.E. from three independent and Proteins—To study how the
experiments.
strength of the poly(A) signal affects
the alternative processing of hERG1
processing of hERG1 pre-mRNA to hERG1a and hERG1aUSO mRNA, we performed mutagenesis in the context of the hERG1
isoforms we constructed a minigene that contained the minigene. When the intron 9 poly(A) signal AGUAAA was
hERG1a cDNA from exon 1 to exon 6 and the genomic changed to the canonical poly(A) signal, AAUAAA, the expressequence spanning intron 6 to the poly(A) signal of the hERG1 sion of hERG1aUSO was increased at both mRNA and protein
gene (Fig. 4A). If intron 9 is spliced out and the poly(A) site in levels, whereas the expression of hERG1a was almost comexon 15 is used, the full-length hERG1a transcript will be pro- pletely inhibited (Fig. 4B and supplemental Fig. S3A, lane 2). In
duced. If the minigene transcript is polyadenylated at the intron contrast, mutation of the intron 9 poly(A) signal from
9 poly(A) site, the hERG1aUSO transcript will be generated. We AGUAAA to CGCAAA resulted in a significant decrease in the
transfected the minigene into Flp-In HEK293 cells and ana- levels of hERG1aUSO mRNA and protein, which was accompalyzed the expressed mRNA by RPA. We designed a probe to nied by a reciprocal increase in the expression of hERG1a
span regions of exons 9 and 10. This probe protects a 309-nt mRNA and protein (Fig. 4B and supplemental Fig. S3A, lane 3).
fragment of the hERG1a transcript and a 210-nt fragment of the These results indicate that the strength of the intron 9 poly(A)
hERG1aUSO transcript. The length of the probe was 440 nt and signal plays an important role in determining the relative
contained sequences from the pCRII vector at both ends. As expression of hERG1a and hERG1aUSO. A strong poly(A) signal
shown in Fig. 4B, both the 309- and 210-nt fragments were results in the predominant production of hERG1aUSO, whereas
observed in the minigene RPA experiments. The hERG1aUSO to the elimination of the poly(A) signal increases the efficiency of
hERG1a (hERG1aUSO/hERG1a) expression ratio was 1.9 ⫾ 0.1 splicing from exon 9 to exon 10, leading to the predominant
(n ⫽ 3). To confirm the validity of this result, a second probe expression of hERG1a.
was designed, which contains hERG1aUSO sequences from
Weak 5⬘ Splice Site in Intron 9 Contributes to the Regulation
exon 9 to intron 9. A similar hERG1aUSO/hERG1a expression of Alternative Processing of hERG1 Pre-mRNA—To investigate
ratio (2.1 ⫾ 0.1, n ⫽ 3) was obtained in RPA analysis the role of intron 9 splicing in the alternative processing of
(supplemental Fig. S2). These results demonstrate that the hERG1 pre-mRNA, we examined the 5⬘ splice site of intron 9.
hERG1 minigene expressed in HEK293 cells can be alterna- Compared with the consensus 5⬘ splice site sequence (CAG/
tively processed to form hERG1a and hERG1aUSO transcripts. gtaagt), the 5⬘ splice site of hERG1 intron 9 (TGG/gtatgg) deviTo determine whether the minigene can produce hERG1a ates at four positions (Fig. 5A). We hypothesized that the deviand hERG1aUSO proteins, we performed immunoblot anal- ation of the 5⬘ splice site from the consensus accounts for the
ysis using an antibody that recognizes both hERG1a and low efficiency of intron 9 splicing. To test this possibility, we
OCTOBER 15, 2010 • VOLUME 285 • NUMBER 42
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FIGURE 5. Effect of 5ⴕ splice site mutations on the alternative processing
of hERG1 mRNA. A, schematic representation of the 5⬘ splice site sequence
and mutations. B, RPA analysis of the minigenes carrying the wild-type (WT),
5⬘ splice site mutation ⫹4U⬎A/⫹6G⬎U (⫹4⫹6), canonical (Can) intron 9
poly(A) signal, and ⫹4U⬎A/⫹6G⬎U plus canonical poly(A) signal mutation
(⫹4⫹6/Can). The expression level of the hygromycin B resistance gene
served as the loading control. Results shown are representative of three independent experiments.

increased the strength of this site by mutating the nucleotides at
the highly conserved ⫹4 and ⫹6 positions toward the consensus sequence in the hERG1 minigene. When the ⫹4U⬎A and
⫹6G⬎U mutations were introduced into the hERG1 minigene,
hERG1a was exclusively produced at the mRNA and protein
levels (Fig. 5B and supplemental Fig. S3B, lane 2). This result
indicates that the 5⬘ splice site of hERG1 intron 9 is intrinsically
weak, and suggests that the presence of a strong 5⬘ splice site
would preclude the formation of hERG1aUSO.
The above experiments demonstrate that both the 5⬘ splicing
and poly(A) signals of hERG1 intron 9 are weak. Increasing the
strength of the poly(A) signal results in the predominant production of hERG1aUSO, whereas increasing the strength of
the 5⬘ splicing signal leads to the predominant production of
hERG1a. To further study the competition between these
two reactions, we introduced the ⫹4U⬎A and ⫹6G⬎U
mutations into the hERG1 minigene containing the canonical poly(A) signal. This change resulted in the reversal of the
predominant production of hERG1aUSO to the predominant
production of hERG1a at the mRNA and protein levels (Fig. 5B
and supplemental Fig. S3B, lanes 4 and 5). These results indicate that a strong 5⬘ splicing signal can outcompete not only the
noncanonical poly(A) signal in intron 9 but also a poly(A) signal
with the canonical sequence. Thus, the relative strengths of 5⬘
splice site and the poly(A) signal in intron 9 are important for
alternative processing of hERG1 pre-mRNA.
Alternative Processing of hERG1 Pre-mRNA Regulates hERG1
Channel Function—To study functional properties of hERG1
channels expressed from the minigene constructs, we performed patch clamp experiments. As controls, we first studied
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FIGURE 6. Voltage clamp recordings of hERG1 currents from minigenes
and cDNAs expressed in HEK293 cells. A and B, representative currents
recorded from cells transfected with hERG1a or hERG1aUSO cDNA. C–F, representative currents recorded from cells transfected with the minigenes carrying the wild-type (WT), canonical (Can), and mutant (Mut) intron 9 poly(A)
signals, and 5⬘ splice site mutation ⫹4U⬎A/⫹6G⬎U (⫹4⫹6). G, histogram
showing the averaged tail current density measured at ⫺50 mV following a
4-s depolarizing pulse to 20 mV for hERG1a cDNA (n ⫽ 8), hERG1aUSO cDNA
(n ⫽ 9), wild-type minigene (n ⫽ 13), minigene with canonical intron 9 poly(A)
signal (n ⫽ 11), minigene with mutant intron 9 poly(A) signal (n ⫽ 12), and
minigene with 5⬘ splice site mutation ⫹4U⬎A/⫹6G⬎U (n ⫽ 8).

the hERG1 currents generated by hERG1a and hERG1aUSO
cDNA. hERG1 current was activated by depolarizing steps
between ⫺70 and 50 mV from a holding potential of ⫺80 mV.
The hERG1 tail current was recorded following repolarization
to ⫺50 mV. Similar to previous reports (10, 11, 20), hERG1a
cDNA produced a typical hERG1 current (Fig. 6A), whereas
cells transfected with hERG1aUSO cDNA did not express the
hERG1 current (Fig. 6B). The hERG1 minigene produced the
hERG1 current, but the current amplitude was reduced compared with the hERG1a cDNA (Fig. 6C). The tail current amplitudes for hERG1a cDNA and the minigene were 19.2 ⫾ 1.5 (n ⫽
8) and 8.3 ⫾ 0.8 pA/pF (n ⫽ 13, p ⬍ 0.05), respectively (Fig. 6G).
The reduced current amplitude in the hERG1 minigene is consistent with the RPA experiments, in which only about onethird of minigene transcripts were processed to the functional
hERG1a isoform.
To study if hERG1 channel function is modulated by the
relative expression of hERG1a and hERG1aUSO we recorded
current from cells transfected with minigenes containing mutations that alter the strength of the 5⬘ splice site and intron 9
poly(A) signal. hERG1 current was nearly abolished by the
AGUAAA to AAUAAA poly(A) signal mutation (Fig. 6D),
whereas the hERG1 current was significantly increased in the
AGUAAA to CGCAAA poly(A) signal mutation (Fig. 6E). The
tail current amplitudes for AAUAAA and CGCAAA mutations
VOLUME 285 • NUMBER 42 • OCTOBER 15, 2010
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sion ratio was higher in the heart than in the brain (Fig. 7B). The
averaged hERG1USO/hERG1FL expression ratios in the heart
and brain were 2.22 ⫾ 0.41 and 0.98 ⫾ 0.08, respectively (n ⫽ 3
individuals). These results indicate that alternative processing
of hERG1 pre-mRNA is regulated in a tissue-specific manner.

FIGURE 7. Real time RT-PCR analysis of relative expression of hERG1
C-terminal isoforms in different human tissues. Quantitative expression of
hERG1FL and hERG1USO transcripts in human tissues was analyzed by real time
PCR. The levels of hERG1 transcripts are normalized to the level of the GAPDH.
Data are shown as the mean ⫾ S.E. from three independent experiments.
A, expression level of hERG1FL and hERG1USO in different tissues. The
hERG1USO/hERG1FL expression ratios for heart, brain, colon, lung, and pancreas were 2.08, 0.96, 1.68, 1.94, and 1.31, respectively. B, expression level of
hERG1FL and hERG1USO in the hearts and brains from three individuals.

were 0.9 ⫾ 0.1 pA/pF (n ⫽ 11, p ⬍ 0.05 compared with the
wild-type minigene) and 19.8 ⫾ 1.7 pA/pF (n ⫽ 12, p ⬍ 0.05
compared with the wild-type minigene), respectively (Fig. 6G).
The 5⬘ splice site mutations ⫹4U⬎A/⫹6G⬎U increased
hERG1 tail current amplitude (18.6 ⫾ 0.9 pA/pF, n ⫽ 8, p ⬍
0.05 compared with the wild-type minigene) (Fig. 6F, G). The
expression levels of hERG1 current generated from the minigene with the AGUAAA to CGCAAA and the ⫹4U⬎A/
⫹6G⬎U mutations were comparable with that of the hERG1a
cDNA. These findings are consistent with the immunoblot
experiments and suggest that changes in the relative expression
of hERG1a and hERG1aUSO can modulate functional expression of hERG1 channels.
Differential Expression of hERG1 C-terminal Isoforms in Human Tissues—Many genes that undergo alternative RNA processing exhibit tissue-specific regulation (28 –30). To determine
whether alternative processing of hERG1 pre-mRNA is regulated in a tissue-specific context, we analyzed the relative
expression levels of hERG1FL and hERG1USO in different tissues by real time RT-PCR. Quantitative RT-PCR revealed that
the relative abundance of hERG1 C-terminal isoforms exhibited significant variation in different human tissues (Fig. 7A).
The hERG1USO/hERG1FL expression ratio was highest in the
heart (2.08) and lowest in the brain (0.96). To further study
the hERG1USO/hERG1FL expression ratio in heart and brain, we
analyzed both heart and brain RNA samples from the same
individuals. In each individual the hERG1USO/hERG1FL expresOCTOBER 15, 2010 • VOLUME 285 • NUMBER 42

DISCUSSION
Polyadenylation is essential for 3⬘-end formation of mRNA
in eukaryotes. It involves two tightly coupled steps: the cleavage
of the nascent pre-mRNA and the addition of a 3⬘ poly(A) tail
(31, 32). The poly(A) signal is defined by the hexamer
AAUAAA, or a one-base variant, found 11–23 nt upstream
from the cleavage site. A downstream U- or GU-rich element,
located ⬍30 nt from the cleavage site, is also required for the
formation of the poly(A) tail. Bioinformatic analyses of poly(A)
signals indicate that as many as 50% of human genes contain
multiple poly(A) signals and ⬃20% human genes have at least
one intronic poly(A) signal (30, 33, 34). The use of intronic
poly(A) sites is often coupled with alternative splicing. The
present findings demonstrate that hERG1 C-terminal isoforms
are generated by alternative processing of a single pre-mRNA
precursor by use of alternative splice or polyadenylation sites.
hERG1a is produced by splicing from exon 9 to 10 and use of a
poly(A) signal in exon 15, whereas hERG1aUSO is generated by
the silencing of the intron 9 5⬘ splice site and the activation of a
poly(A) site in intron 9. The poly(A) signal within intron 9 of the
hERG1 gene consists of a noncanonical hexamer, AGUAAA.
Although the canonical hexamer AAUAAA is the most widely
used poly(A) signal, the AGUAAA sequence has been reported
to occur with a frequency of 5– 8% in human genes (24). Furthermore, several putative U/GU-rich elements are present
downstream of the AGUAAA poly(A) signal (supplemental
Fig. S1). The poly(A) competition assay shows that the
AGUAAA and surrounding sequences in hERG1 intron 9 are
capable of eliciting polyadenylation in a tandem poly(A) signal
construct. Mutational analysis confirmed the identity of the
AGUAAA hexamer as a relatively weak, poly(A) signal in intron
9 of the hERG1 gene.
Although the intron 9 poly(A) signal is weak, approximately
two-thirds of hERG1 pre-mRNA is processed to hERG1USO in
the heart. This is due to the presence of a weak 5⬘ splice site in
intron 9. When the 5⬘ splice site of intron 9 is mutated toward
the consensus sequence, the splicing reaction dominates over
polyadenylation, leading to the predominant expression of
hERG1a. In contrast, when the noncanonical intron 9 poly(A)
signal is changed to the strong, canonical poly(A) signal, polyadenylation becomes the dominant reaction, leading to predominant expression of hERG1aUSO. These results suggest that
the relative strengths of the 5⬘ splice site and poly(A) signal of
intron 9 contributes to the alternative processing of hERG1
pre-mRNA. This notion is also supported by the finding that
elimination of the intron 9 poly(A) signal by the AGUAAA to
CGCAAA mutation results in predominant expression of
hERG1a. Thus, the inefficient splicing observed in hERG1
pre-mRNA in the minigene experiment is due to the presence
of the competing poly(A) signal in intron 9. These findings suggest that the proper balance between splicing and polyadenylation efficiencies, mediated by intrinsically weak splicing and
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poly(A) signals, is important for the alternative processing of
hERG1 mRNA and the relative expression of hERG1a and
hERG1aUSO isoforms.
Our results show that the relative abundance of hERG1
C-terminal isoforms varies in different tissues, suggesting that
alternative processing of hERG1 pre-mRNA is regulated in a
tissue-specific manner. Regulation of gene expression by alternative processing of pre-mRNA has been reported in many
genes (28 –30, 35, 36). A well studied example is the regulation
of the IgM heavy chain gene during B cell differentiation (28,
36). In developing B cells, a membrane-bound form of IgM
heavy chain is produced through splicing of intron 4 and the
utilization of the poly(A) signal in exon 6. In mature plasma
cells, a relatively weak intronic polyadenylation site within
intron 4 is used, leading to the predominant production of the
secreted form of IgM heavy chain. This regulation depends on
the competition between splicing and polyadenylation. The
ratio of membrane-bound to secreted forms of IgM mRNA is
regulated by the relative efficiencies of these two reactions (36).
Our findings suggest that a similar mechanism may contribute
to the generation of hERG1 C-terminal isoforms. Altering
splicing and polyadenylation efficiencies by mutating the splicing and poly(A) signals in hERG1 intron 9 is sufficient to shift
the alternative processing of hERG1 pre-mRNA toward the
hERG1a or hERG1aUSO pathway. It is conceivable that the efficiencies of splicing and polyadenylation of hERG1 intron 9 vary
in different tissues, leading to the observed differential expression of hERG1 C-terminal isoforms.
Functional studies show that changes in the relative expression ratio of hERG1a and hERG1aUSO modulate hERG1 channel function. Although the hERG1aUSO isoform does not form
functional channels, changes in the expression level of
hERG1aUSO may regulate hERG1 channel function through
post-transcriptional and post-translational mechanisms.
Because hERG1a and hERG1aUSO are produced from alternative processing of a single pre-mRNA precursor, an increase in
hERG1aUSO would limit the production of full-length hERG1a,
whereas a decrease in hERG1aUSO would allow a given
pre-mRNA transcript to be processed to the functional hERG1a
isoform. In our minigene experiments, a decrease or increase in
hERG1aUSO expression induced by 5⬘ splice site and poly(A)
signal mutations is always accompanied by a reciprocal increase
or decrease in hERG1a. These findings suggest that alternative
processing of hERG1 pre-mRNA represents a novel post-transcriptional mechanism that regulates the expression level of the
hERG1a isoform, and thereby hERG1 channel function. Alternative processing of hERG1 pre-mRNA may also regulate
hERG1 channel function through a post-translational mechanism as recently proposed by Guasti et al. (11), who showed that
the hERG1USO isoforms coassemble with hERG1a/b and inhibit
hERG1 channel function. Thus, differential expression of
hERG1 C-terminal isoforms mediated by the alternative processing of hERG1 pre-mRNA may play an important role in
modulating hERG1 channel function and electrophysiological
properties in different tissues.
In summary, our results demonstrate that hERG1 C-terminal
isoforms are generated by alternative splicing and polyadenylation of hERG1 intron 9. The alternative processing of hERG1
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pre-mRNA is regulated in a tissue-specific manner. This regulation depends on the relative efficiencies of RNA splicing and
polyadenylation events. The alternative processing of hERG1
pre-mRNA may represent a novel post-transcriptional mechanism to modulate the expression and function of hERG1
channels.
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